|
|||||
|
|
Defining acceptable epidemiology ranges in donor populations based on the contamination risk of finished plasma‐derived products |
|
| Authors: | S. Lovick K. Bycholski A. Gröner |
| Affiliation: | 1. Synergies Economic Consulting, , Melbourne, Vic., Australia;2. CSL Plasma, , Boca Raton, FL, USA;3. CSL Behring, , Marburg, Germany |
| Abstract: | |
| Keywords: | epidemiology HBV HCV HIV plasma pool |